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Surgical Site Infection in Venous Surgery: The Benefit
of a Single Dose of Preoperative Antibiotic
Ranjodh Singh1, Amir Aryaie1, Alok Dwivedi3, Brent
Marsden1, Rakesh Shukla3, Alan Annenberg2, Gregory
Zenni2, Charles Mesh1. 1Department of Surgery, Jewish
Hospital, Cincinnati, OH; 2Cardiac, Vascular, and Tho-
racic Surgeons, Inc., Cincinnati, OH; 3Center for Biosta-
tistical Services, Department of Environmental Health,
College of Medicine, University of Cincinnati, Cincinnati,
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Objectives: High ligation and division (L/D) of the
saphenofemoral junction (SFJ) can protect against the dan-
ger of thromboembolism (TE) associated with greater sa-
phenous vein radiofrequency ablation (GSV RFA). Al-
though L/D SFJ is regarded as a clean procedure, surgical
site infection (SSI) can offset its TE benefit. We questioned
if SSI associated with SFJ L/D could be minimized by a
single pre-operative dose of antibiotic (ABx).
Methods: A retrospective cohort study of ABx in GSV
RFA and L/D SFJ was conducted in a population of 953
consecutive limbs (April 2002 to December, 2010; Venous
Severity Score 1 to 3) with the single outcome measure of
SSI. Controls (April 2002 to July 2006) received no ABx.
SSI was categorized based on required therapy: 0-none,
1-oral ABx, and 2-hospitalization for intravenous ABx
and/or wound debridement. Statistical analysis included
unpaired Student’s t-test for quantitative measures, Fisch-
er’s exact for categorical variables, and multiple logistic
regression to assess effect of Abx on SSI after adjustment for
age, body mass index (BMI), and diabetes (DM).
Results: Total SSI and groin SSI rates are shown in
Table 1. All category 2 SSI (n8) occurred in controls and
the majority were located in the groin. BMI and DM
significantly increased risk for groin SSI. ABx significantly
reduced both overall SSI risk [OR:0.55; (95%CI: 0.33,
0.90), p0.02] and groin SSI risk [OR:0.36; (95%CI:0.17,
0.76), p0.01]. Finally, ABX eliminated category 2 SSI
(p0.045).
Conclusions: L/D SFJ and RFA, when treated as a
clean procedure and not prophylaxed with Abx, carries a
significant risk of SSI. While DM and BMI are patient-
associated risk factors, a single dose of preoperative antibi-
otic significantly reduces the rate of all SSI and eliminates
the danger of serious infection requiring hospitalization.
Surgical Site Infection
Total
(n953)
No ABx
(n504)
ABx
(n449) p-value
Groin (n/%) 37/3.88 27/5.36 10/2.23 0.02
Total (n/%) 78/8.18 50/9.92 28/6.24 0.04
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Timing of TEVAR Does Not Influence Mortality After
Hybrid Repair of Thoracoabdominal Aneurysms
Nathan J. Aranson, Emel Ergul, Virendra I. Patel, Glenn
M. LaMuraglia, Christopher J. Kwolek, Richard P. Cam-
bria, Mark F. Conrad. Massachusetts General Hospital,
Boston, MA
Introduction: Thoracoabdominal aneurysm (TAA)
repair carries significant morbidity and mortality. A hybrid
approach involving open visceral vessel debranching fol-
lowed by TEVAR may decrease perioperative mortality;
however, the optimal timing of TEVAR is controversial.
The study goal was to determine the effect of TEVAR
timing on mortality.
Methods: ICD-9 codes were used to retrospectively
identify patients with intact TAA who underwent visceral
vessel debranching and TEVAR from 2004-2007 in the
Medicare database. Patients were divided into two cohorts:
immediate and delayed TEVAR. The primary outcome was
mortality; secondary outcomes included morbidity, length
of stay(LOS), and cost.
Results: Four-hundred-ninety-four patients were
identified (75% immediate v. 25% delayed). There was no
difference in 30-day mortality (7.3% immediate v. 4.0%
delayed, p0.29). Immediate cohort patients were more
likely to be males (70% immediate v. 53% delayed,
p0.006) and without chronic renal insufficiency (9.5%
immediate v. 21.5% delayed, p0.006). Postoperative
morbidity, including renal insufficiency, was similar in both
cohorts except that the delayed group developed more
pulmonary complications (14.3% immediate v. 24.1% de-
layed, p0.042). As expected, delayed cohort patients had
a longer hospital LOS (10.110.9 immediate v.
19.817.0 delayed, p0.001) and ICU LOS (5.18.5
immediate v. 10.613.5 delayed, p0.001). The mean
hospitalization cost was also higher ($176,552 immediate
v. $273,355 delayed, p0.001). The 3-year actuarial sur-
vival was similar between cohorts (59% immediate vs. 57%
delayed, p0.524).
Conclusions: The timing of TEVAR for hybrid TAA
repair does not influence mortality or postoperative renal
function. However, delaying TEVAR is associated with
increased pulmonary complications, longer LOS and
higher hospitalization cost.
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